Rare diseases
The Alcimed Healthcare team has been exploring the rare disease market, often called orphan diseases, for more than 25 years, and supports its clients in their innovation projects, in understanding the orphan drug market and in their market access approaches.
THE CHALLENGES RELATED TO RARE DISEASES OR ORPHAN DISEASES
-
What is a rare disease and what is an orphan drug?
A “rare disease” is when a disease affects a very small proportion of the population, generally less than 8 people in 10,000.
An “orphan drug” is a drug that obtains privileged regulatory status from the authorities (the “orphan designation”) intended to encourage the development of therapies for these orphan diseases.
-
What are the challenges related to rare diseases?
The rare disease market is experiencing strong growth and transformation across the world. Over 230 orphan drugs have been approved on the European market since early 2000.
As a result, the typology of rare diseases, their challenges and their market situations are evolving significantly. This term now includes:
- ultra-rare pathologies without any suitable medical solution,
- relatively unknown rare diseases still awaiting solutions,
- rare but well-known pathologies, with several treatment options, representing considerable progress for patients in established markets that are more similar to so-called “specialty” markets.
Even though this market is developing, manufacturers, biotechs and research centers are facing many challenges, including:
Rare and orphan diseases, in particular those with a strong genetic component, have regularly been the focus of the development and use of new advanced (bio)therapies. After different generations of recombinant proteins (replacement, chaperones, etc.), therapy and gene modification approaches (expression of transfected genes, gene modification in vivo, siRNA, saRNA, mRNA, etc.) offer a new wave of transformative hope for patients with these rare diseases and remain a real field of exploration.
What are the most relevant new technologies to continue transforming the field of rare diseases? Which technological approach should target which disease and how can the current limits to address all sub-populations be overcome?
What are the most relevant new technologies to continue transforming the field of rare diseases? Which technological approach should target which disease and how can the current limits to address all sub-populations be overcome?
Recruiting patients is more complex for an orphan drug because the population is small and often poorly identified. The comorbidities associated with most genetic diseases often complicate the analysis of the results, and it can be difficult to establish criteria for clinical evaluation and appropriate biomarkers. How many patients are affected and how can patients be found for a clinical trial?
How many patients are affected and how can patients be found for a clinical trial?
How many patients are affected and how can patients be found for a clinical trial?
Orphan diseases are often difficult to diagnose because the level of awareness is low. Although they are sometimes helped by patient associations, pharmaceutical players very often have to "create" the market by raising awareness and educating doctors and authorities on the targeted disease and by structuring the organization of the patient journey.
How can healthcare professionals and authorities find out about this rare disease and the existence of a treatment?
How can healthcare professionals and authorities find out about this rare disease and the existence of a treatment?
The paths to register a new orphan drug and to obtain reimbursement differ from one country to another, as do the regulations and the actors involved. Different acceleration and market access strategies exist for these very specific drugs, and are often specific to each country. Also, access frameworks and the preferences of healthcare product evaluators are changing rapidly for orphan drugs and offer new possibilities or new challenges.
What is the regulatory framework and what path should be taken to obtain and accelerate the marketing of an orphan drug?
What is the regulatory framework and what path should be taken to obtain and accelerate the marketing of an orphan drug?
Prices per treatment can be very high and affordability of orphan drugs has become a major issue for payers as the number of orphan drugs increases dramatically. How will a drug be assessed and possibly reimbursed in a given country? At what price should the treatment be positioned? How can its value be shown?
How will a drug be assessed and possibly reimbursed in a given country? At what price should the treatment be positioned? How can its value be shown?
How will a drug be assessed and possibly reimbursed in a given country? At what price should the treatment be positioned? How can its value be shown?
Healthcare professionals are either not used to dealing patients with rare diseases, or they are not used to having many of these "rare" patients. This makes diagnosis often difficult and time-consuming, as is the coordination between the different actors throughout the patient pathway.
How can care pathways be organized and optimized to improve the level of diagnosis and accessibility to treatment?
How can care pathways be organized and optimized to improve the level of diagnosis and accessibility to treatment?
HOW DO WE SUPPORT YOU IN YOUR RARE DISEASES OR ORPHAN DISEASES PROJECTS?
For more than 25 years, Alcimed has been supporting its clients on many issues related to orphan and ultra-orphan diseases, in Oncology and outside Oncology. Indeed, we have carried out more than 150 projects in this field on more than 100 rare diseases for different actors such as:
- National and European institutions and research centers (for example, the European Commission, INCa, AFM / Genethon)
- European and North American biopharmaceutical and pharmaceutical companies, biotechnology companies and professional associations (e.g. Genzyme (Sanofi), Shire (Takeda), Endo, Amgen, Chiron, Actelion (J&J), Alexion (Astrazeneca), PTC Therapeutics, Vertex, Sanofi, J&J, Roche, Merck-Serono, Novartis, Novagali (Santen), Spark Therapeutics (Roche), Insmed, Bone Therapeutics, Cellectis, NPS Pharma (Takeda), Intermune (Roche), EFPIA, EBE, EuropaBio etc.)
- Patient associations (e.g. SFPA).
The diversity of our clients (industrial companies, biotechs, research institutes, professional associations, national or European institutes, etc.), the geographic areas we explore, and the types of projects we develop, give us a global and in-depth understanding of the issues related to rare diseases.
Our projects cover areas as diverse as new technologies and therapeutic approaches for orphan diseases, search for funding opportunities, preparation for the launch of new orphan drugs, understanding of disease management and patient care pathways, assessment of market and licensing opportunities, market access, pricing and reimbursement models, regulatory developments and operational support (patient identification, care pathways optimization and many more).
The types of projects we carry out for our clients in this field are:
|
|
|
A project? Contact our explorers!
EXAMPLES OF RECENT PROJECTS CARRIED OUT FOR OUR CLIENTS IN RARE DISEASES
One of our clients, a leading pharmaceutical player, wanted to improve the care of patients with a rare disease by developing a high value-added service offering that improves their well-being and quality of life throughout their care pathways (from diagnosis to palliative care).
To do this, our team interviewed patients, caregivers and associations in each country concerned in order to identify the levers for improving their well-being and their quality of life that could be addressed by the development of services. Following this, our team pre-tested these service ideas with healthcare professionals, before organizing a workshop to co-construct a service development roadmap with the medical and marketing teams of our client. Ultimately, several services were deployed in pilot countries and then extended to other countries in the area, improving the patient journey and positioning our client as a major player in public health.
To do this, our team interviewed patients, caregivers and associations in each country concerned in order to identify the levers for improving their well-being and their quality of life that could be addressed by the development of services. Following this, our team pre-tested these service ideas with healthcare professionals, before organizing a workshop to co-construct a service development roadmap with the medical and marketing teams of our client. Ultimately, several services were deployed in pilot countries and then extended to other countries in the area, improving the patient journey and positioning our client as a major player in public health.
Alcimed supported a US biopharmaceutical client to define the launch strategy for its orphan drug in Europe. It then helped its client to structure a concrete and operational plan, both at a European level as well for each target country. As a real roadmap for each of the key functions of the company (medical, marketing, production, regulatory, sales), the plan extends from pre-launch (before obtaining the MA, the Marketing Authorization) until the first sales. Our team is also involved in regularly updating this plan, depending on internal or external developments around this launch.
We have supported the European Medical Department of a pharmaceutical manufacturer in optimizing the care pathway for patients suffering from a rare respiratory disease in several European countries. As this rare disease is difficult to diagnose and often confused with more common respiratory diseases, the patient diagnosis time was too long (2 to 3 years). Our client wanted to position itself as a public health player by providing reference hospitals with Alcimed's service to:
1. Diagnose the current coordination of care between the different health actors registered on the patient journey
2. Co-define with this multidisciplinary team an ideal patient care model and an associated action plan
3. Implement actions defined at local and national level.
The result for our client? A reduction in the time taken to diagnose patients and a general improvement in physician coordination, an increase in therapeutic support and a change of perspective for the sales teams.
1. Diagnose the current coordination of care between the different health actors registered on the patient journey
2. Co-define with this multidisciplinary team an ideal patient care model and an associated action plan
3. Implement actions defined at local and national level.
The result for our client? A reduction in the time taken to diagnose patients and a general improvement in physician coordination, an increase in therapeutic support and a change of perspective for the sales teams.
Support for a player in the pharmaceutical industry in understanding the fundamental factors of market access for orphan drugs in 9 emerging countries. By taking stock of internal knowledge and collecting missing information in terms of the market and regulatory analysis in particular, Alcimed has enabled its client to obtain an overview of the regulations on orphan drugs in emerging countries and to classify these countries according to their level of accessibility.
Founded in 1993, Alcimed is an innovation and new business consulting firm, specializing in innovation driven sectors: life sciences (healthcare, biotech, agrifood), energy, environment, mobility, chemicals, materials, cosmetics, aeronautics, space and defence.
Our purpose? Helping both private and public decision-makers explore and develop their uncharted territories: new technologies, new offers, new geographies, possible futures, and new ways to innovate.
Located across eight offices around the world (France, Europe, Singapore and the United States), our team is made up of 220 highly-qualified, multicultural and passionate explorers, with a blended science/technology and business culture.
Our dream? To build a team of 1,000 explorers, to design tomorrow's world hand in hand with our clients.
Our purpose? Helping both private and public decision-makers explore and develop their uncharted territories: new technologies, new offers, new geographies, possible futures, and new ways to innovate.
Located across eight offices around the world (France, Europe, Singapore and the United States), our team is made up of 220 highly-qualified, multicultural and passionate explorers, with a blended science/technology and business culture.
Our dream? To build a team of 1,000 explorers, to design tomorrow's world hand in hand with our clients.
Our explorations
- Proof of concept
- Voice of Customer (VOC)
- Activation
- Benchmark
- Business case
- Business development
- Business models
- Business plan
- Cluster study
- Collaborative projects
- Commercial strategy
- Competitive analysis
- Customer experience
- Diversification
- Dossier creation
- Due diligence
- Go to market
- Innovation consulting
- Innovation process
- Innovation strategy
- Learning expedition
- Market access
- Market study
- New offers
- New services
- Open innovation
- Opportunity evaluation
- Patient pathway
- Product innovation
- Product launch
- Regulatory framework analysis
- Roadmap
- Scouting
- Search for funding opportunities
- Search for partners
- State of the art
- Strategic audit
- Strategic foresight
- Strategic positioning
- Test and Learn
- Valorization
- Value proposition
- Workshops